Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab compared with neoadjuvant chemotherapy alone in patients with early-stage non-small-cell lung cancer (KEYNOTE-671): a randomised, double-blind, placebo-controlled, phase 3 trial
Jonathan Spicer(Chinese Academy of Medical Sciences & Peking Union Medical College), Silvia Novello(University of Turin), E. Eigendorff(Chinese Academy of Medical Sciences & Peking Union Medical College), Moïshe Liberman(Chinese Academy of Medical Sciences & Peking Union Medical College), Christophe Dooms(Chinese Academy of Medical Sciences & Peking Union Medical College), Shugeng Gao(Chinese Academy of Medical Sciences & Peking Union Medical College), Heather A. Wakelee(Palo Alto Institute), Ashwini Arunachalam(Merck & Co., Inc., Rahway, NJ, USA (United States)), Olivier Bylicki(Chinese Academy of Medical Sciences & Peking Union Medical College), Masahiro Tsuboi(National Cancer Center Hospital East), Ayman Samkari(Merck & Co., Inc., Rahway, NJ, USA (United States)), Delvys Rodríguez‐Abreu(Universidad de Las Palmas de Gran Canaria), Margarita Majem(Chinese Academy of Medical Sciences & Peking Union Medical College), Se‐Hoon Lee(Samsung Medical Center), Gastón Lucas Martinengo(Chinese Academy of Medical Sciences & Peking Union Medical College), Jamie E. Chaft(Memorial Sloan Kettering Cancer Center), Terufumi Kato(Taipei Veterans General Hospital), Marina Chiara Garassino(University of Chicago), Jing Yang(Merck & Co., Inc., Rahway, NJ, USA (United States)), Ke‐Neng Chen(Chinese Academy of Medical Sciences & Peking Union Medical College), Steven M. Keller(Merck & Co., Inc., Rahway, NJ, USA (United States))
Cited by 233
Related Papers
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
|The Lancet Oncology|2012|5.5k
International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma
|Journal of Thoracic Oncology|2011|4.8k
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
|Nature Genetics|2019|4.4k
Osimertinib or Platinum–Pemetrexed in <i>EGFR</i> T790M–Positive Lung Cancer
|New England Journal of Medicine|2016|3.3k
Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With <i>EGFR</i> Mutations
|Journal of Clinical Oncology|2013|3.2k